Growing Mid-Tier Pharmaceutical Company Awards $1.4 Million Late Phase Study to eResearchTechnology Agreement Illustrates Continued Trend Toward Robust Phase III Cardiac Safety Monitoring Following the Finalization of International Regulatory Guidance PHILADELPHIA, June 14 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT) (NASDAQ:ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has been awarded about $1.4 million in cardiac safety monitoring and services for a late phase development program from a growing mid-tier pharmaceutical for one of its key new drug candidates in development. The award covers a significant Phase III study. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. "This award is illustrative of the robust cardiac safety monitoring in later phase clinical development that is referenced in the recently finalized international regulatory guidance," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "eRT is uniquely equipped to meet the full range of cardiac safety services required by today's drug development community - from extensive later phase programs, as represented by this contract, to focused Thorough QT studies." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsor may cancel this agreement at its sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci of eResearchTechnology, +1-908-203-6473 or Matt Hayden of Hayden Communications, +1-858-704-5065 Web site: http://www.ert.com/

Copyright

East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more East Resources Acquisition Charts.
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more East Resources Acquisition Charts.